P
Phio Pharmaceuticals Corp. (PHIO)
NCM – Real vaqt narxi. Valyuta: USD
1.10
+0.02 (1.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.10
+0.02 (1.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Phio Pharmaceuticals Corp., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda immuno-onkologiya terapiyasini ishlab chiqish bilan shug'ullanadi. U ko'p markazli 1b-bosqichli dozani oshiruvchi klinik tadqiqotlarda PD-1 ekspressiyasini kamaytirish uchun mo'ljallangan INTASYL birikmasi PH-762; preklinik tadqiqotlarda T-hujayralari va o'sma hujayralarida gen ekspressiyasini boshqaradigan BRD4 oqsilini maxsus jim qilish uchun mo'ljallangan INTASYL birikmasi PH-894ni ishlab chiqadi. Kompaniya ilgari RXi Pharmaceuticals Corporation nomi bilan tanilgan va 2018-yil noyabr oyida Phio Pharmaceuticals Corp. nomini olgan. Phio Pharmaceuticals Corp. 2003-yilda tashkil etilgan va King Of Prussia, Pensilvaniya shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jennifer Phillips Pharm.D. | Senior Vice President of Regulatory & Corporate Affairs |
| Mr. Robert J. Bitterman | President, CEO & Chairman |
| Ms. Linda M. Mahoney | Senior Vice President of Development |
| Ms. Lisa C. Carson | CFO, Principal Accounting Officer and VP of Finance & Administration |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | phio20260331_8k.htm |
| 2026-05-07 | 10-Q | phio20260331_10q.htm |
| 2026-04-08 | 8-K | phio20260402_8k.htm |
| 2026-03-30 | 8-K | phio20260326_8k.htm |
| 2026-03-05 | 8-K | phio20251215_8k.htm |
| 2026-02-18 | 8-K | phio20260216_8k.htm |
| 2026-02-10 | 8-K | phio20260206_8k.htm |
| 2026-01-20 | 8-K | phio20260113_8k.htm |
| 2025-12-23 | 8-K | phio20251222_8k.htm |
| 2025-12-01 | CORRESP | filename1.htm |